Nexalin Technology, Inc. (NXL)

NASDAQ: NXL · IEX Real-Time Price · USD
1.10
+0.04 (3.77%)
At close: Feb 1, 2023, 4:00 PM
1.03
-0.07 (-6.36%)
After-hours: Feb 1, 2023, 5:23 PM EST
3.77%
Market Cap 8.01M
Revenue (ttm) 1.31M
Net Income (ttm) -1.56M
Shares Out 7.28M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,261
Open 1.06
Previous Close 1.06
Day's Range 1.00 - 1.10
52-Week Range 0.65 - 3.23
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 9, 2023

About NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Sep 16, 2022
Employees 2
Stock Exchange NASDAQ
Ticker Symbol NXL
Full Company Profile

Financial Performance

Financial Statements

News

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of Michael Nketiah as Senior Vice President of Qu...

1 week ago - GlobeNewsWire

Nexalin Technology CEO Provides Letter to Shareholders

HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today provided the following business update and letter to shareholders from its ...

1 month ago - GlobeNewsWire

Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder

The Second Xiangya Hospital of Central South University, China, reports positive patient results, including disappearance of all somatic anxiety symptoms and improved quality of sleep

2 months ago - GlobeNewsWire

Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering

HOUSTON, TEXAS, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the closing of its previously announced initial public offering of 2,315,000 un...

4 months ago - GlobeNewsWire

Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering

HOUSTON, TEXAS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the pricing of its initial public offering of 2,315,000 units consisting of  2,...

4 months ago - GlobeNewsWire